The Cigna Group stock (US1255091092): Analyst consensus and valuation picture on NYSE CI

The Cigna Group shares on the New York Stock Exchange are trading below many analysts' 12-month targets, with fresh data on 05/28/2026 highlighting a consensus "Moderate Buy" stance and an average price target well above the current level.

The Cigna Group stock on the New York Stock Exchange has been trading in a zone that analysts still view as discounted, with recent data as of 05/28/2026 pointing to a gap between the current CI share price and the average 12-month target set by major brokerages, underscoring the United States-listed health insurer's valuation debate according to MarketBeat as of 05/28/2026.

The stock traded around the high USD 280s in recent sessions on the NYSE, with one snapshot showing CI at USD 286.06 at the close on 05/22/2026 and a market capitalization of roughly USD 75.7 billion, illustrating the scale of this S&P 500 health care name in its home United States market according to MarketBeat as of 05/22/2026.

The latest trading data highlight that CI's share price has fallen about 8 percent over the last 12 months while still gaining roughly 3.9 percent year-to-date as of 05/22/2026, a mixed performance pattern that feeds into the valuation discussion around the group's U.S.-listed equity according to the same MarketBeat chart as of 05/22/2026.

For investors in Germany who follow U.S. health care stocks via local platforms, The Cigna Group is also available on trading venues such as Tradegate under the CI ticker, where it can be traded in euros alongside the primary U.S.-dollar listing, giving cross-border investors exposure to the American health insurance market.

Separate valuation work published in late May 2026 put one estimate of The Cigna Group's fair value at roughly USD 339.58 per share, well above a recent close of USD 285.75, implying room between current market pricing and certain discounted cash flow-derived assessments according to Simply Wall St as of 05/27/2026.

The stock price dynamic has also been influenced by short-term moves, with one daily performance snapshot showing the CI share price moving from USD 280.83 to USD 285.75 and gaining about 1.75 percent in a single session, illustrating that the U.S.-traded stock can display notable daily swings even as the longer-term trajectory over 12 months has been slightly negative according to StockInvest.us data as of 05/27/2026.

The stock's valuation narrative is therefore framed by a combination of modest year-to-date gains, a pullback over the past year, and the perception that current prices sit below many forward-looking fair-value estimates, all in the context of a large-cap U.S. health insurer operating within a heavily regulated domestic market.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: CI
• Sector/industry: Health care / managed care and insurance
• Headquarters/country: Bloomfield, United States
• Core markets: United States, selected international health services markets
• Key revenue drivers: U.S. medical insurance plans, pharmacy benefits and health services
• Home exchange/listing venue: New York Stock Exchange (CI)
• Trading currency: USD

The Cigna Group: core business model

The Cigna Group focuses on providing health insurance and related services, with revenue primarily generated from U.S. medical coverage plans, integrated pharmacy benefits, and associated health services for employers, government programs, and individuals.

Valuation metrics and multiples for The Cigna Group

Recent analyst data compiled on 05/28/2026 show that The Cigna Group has attracted coverage from 21 research firms, with the consensus view summarized as a "Moderate Buy" rating and an average 12-month price target of about USD 339.50, setting the mean analyst objective substantially above the high USD 280s trading range according to MarketBeat as of 05/28/2026.

Another valuation lens from late May 2026, based on discounted cash flow analysis, pointed to an estimated fair value of around USD 339.58 per CI share compared with a recent market price of USD 285.75, a gap that aligns closely with the consensus target and underscores how several external models currently position the stock's intrinsic valuation above the spot price according to Simply Wall St as of 05/27/2026.

Conclusion

The Cigna Group's NYSE-listed shares are currently trading below a cluster of external valuation estimates and analyst price targets, with recent data showing the stock in the high USD 280s while consensus objectives sit closer to the mid-USD 330s. The combination of modest year-to-date gains, a slightly negative 12-month performance, and a sizeable gap to intrinsic value models means that the CI valuation story is likely to remain a key focus for investors following the U.S. health care and managed care space. How this valuation gap evolves over time will depend on future operating performance, sector dynamics, and the broader backdrop for U.S. health care policy and insurance markets.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.